BACKGROUND: Carriers of the FMR1 premutation allele are at a significantly increased risk for a late-onset neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). This disorder is distinct from fragile X syndrome (FXS) in its molecular aetiology and clinical presentation. The primary features of FXTAS are late-onset intention tremor and gait ataxia. Associated features include parkinsonism, neuropsychological dysfunction, autonomic dysfunction and peripheral neuropathy. AIM: To investigate the usefulness of a quantitative neurological test battery implemented through the CATSYS instrument to identify preclinical symptoms of FXTAS. METHODS: Both premutation carriers with 70-199 repeats (62 men) and their low-repeat allele carrier siblings (27 men), identified through families with an individual affected with FXS, were tested. RESULTS: As expected, because of its sensitivity, use of the instrument allowed identification of tremor in 23% of men who had not self-reported tremor, and ataxia in 30% of men who had not self-reported ataxia. Among subjects with self-reported tremor and ataxia, we found significant concordance between measures of the CATSYS system and the self-report. CONCLUSION: Rates of these traits among premutation carriers and low-repeat allele carrier siblings could be identified, and are presented in this paper, along with the minimum estimates of age-related prevalence.
BACKGROUND: Carriers of the FMR1 premutation allele are at a significantly increased risk for a late-onset neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). This disorder is distinct from fragile X syndrome (FXS) in its molecular aetiology and clinical presentation. The primary features of FXTAS are late-onset intention tremor and gait ataxia. Associated features include parkinsonism, neuropsychological dysfunction, autonomic dysfunction and peripheral neuropathy. AIM: To investigate the usefulness of a quantitative neurological test battery implemented through the CATSYS instrument to identify preclinical symptoms of FXTAS. METHODS: Both premutation carriers with 70-199 repeats (62 men) and their low-repeat allele carrier siblings (27 men), identified through families with an individual affected with FXS, were tested. RESULTS: As expected, because of its sensitivity, use of the instrument allowed identification of tremor in 23% of men who had not self-reported tremor, and ataxia in 30% of men who had not self-reported ataxia. Among subjects with self-reported tremor and ataxia, we found significant concordance between measures of the CATSYS system and the self-report. CONCLUSION: Rates of these traits among premutation carriers and low-repeat allele carrier siblings could be identified, and are presented in this paper, along with the minimum estimates of age-related prevalence.
Authors: Danuta Z Loesch; Lucas Litewka; Peter Brotchie; Richard M Huggins; Flora Tassone; Mark Cook Journal: Ann Neurol Date: 2005-08 Impact factor: 10.422
Authors: James A Brunberg; Sebastien Jacquemont; Randi J Hagerman; Elizabeth M Berry-Kravis; Jim Grigsby; Maureen A Leehey; Flora Tassone; W Ted Brown; Claudia M Greco; Paul J Hagerman Journal: AJNR Am J Neuroradiol Date: 2002 Nov-Dec Impact factor: 3.825
Authors: Y H Fu; D P Kuhl; A Pizzuti; M Pieretti; J S Sutcliffe; S Richards; A J Verkerk; J J Holden; R G Fenwick; S T Warren Journal: Cell Date: 1991-12-20 Impact factor: 41.582
Authors: C M Greco; R J Hagerman; F Tassone; A E Chudley; M R Del Bigio; S Jacquemont; M Leehey; P J Hagerman Journal: Brain Date: 2002-08 Impact factor: 13.501
Authors: F Rousseau; D Heitz; V Biancalana; S Blumenfeld; C Kretz; J Boué; N Tommerup; C Van Der Hagen; C DeLozier-Blanchet; M F Croquette Journal: N Engl J Med Date: 1991-12-12 Impact factor: 91.245
Authors: W T Brown; G E Houck; A Jeziorowska; F N Levinson; X Ding; C Dobkin; N Zhong; J Henderson; S S Brooks; E C Jenkins Journal: JAMA Date: 1993-10-06 Impact factor: 56.272
Authors: Sébastien Jacquemont; Randi J Hagerman; Maureen A Leehey; Deborah A Hall; Richard A Levine; James A Brunberg; Lin Zhang; Tristan Jardini; Louise W Gane; Susan W Harris; Kristin Herman; James Grigsby; Claudia M Greco; Elizabeth Berry-Kravis; Flora Tassone; Paul J Hagerman Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: A Schneider; C Johnston; F Tassone; S Sansone; R J Hagerman; E Ferrer; S M Rivera; D Hessl Journal: Clin Neuropsychol Date: 2016-06-29 Impact factor: 3.535
Authors: Melina C Ortigas; James A Bourgeois; Andrea Schneider; John Olichney; Danh V Nguyen; Jennifer B Cogswell; Deborah A Hall; Randi J Hagerman Journal: J Clin Psychopharmacol Date: 2010-10 Impact factor: 3.153
Authors: Joan A O'Keefe; Erin Robertson-Dick; Emily J Dunn; Yan Li; Youping Deng; Amber N Fiutko; Elizabeth Berry-Kravis; Deborah A Hall Journal: Cerebellum Date: 2015-12 Impact factor: 3.847
Authors: Andreea L Seritan; Danh V Nguyen; Yi Mu; Flora Tassone; James A Bourgeois; Andrea Schneider; Jennifer B Cogswell; Kylee R Cook; Maureen A Leehey; Jim Grigsby; John M Olichney; Patrick E Adams; Wendi Legg; Lin Zhang; Paul J Hagerman; Randi J Hagerman Journal: J Clin Psychiatry Date: 2014-03 Impact factor: 4.384